文献速递临床试验与 GCP基础与转化研究

ENACT:辅助性N-乙酰半胱氨酸治疗首发精神病疗效与机制随机安慰剂对照试验方案

ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis.
PubMed 文献 · Trials · 2019-11-28

ENACT是一项26周随机安慰剂对照试验,纳入162名15-25岁首发精神病年轻患者,在澳大利亚墨尔本早期精神病预防与干预中心接受治疗。研究比较辅助性N-乙酰半胱氨酸(2 g/天)与安慰剂对精神症状的疗效,主要终点为第26周PANSS总分,并设26周非治疗随访至第52周,同时探索神经生物学机制。

要点

  • 辅助性NAC 2 g/天持续26周,对照安慰剂,主要终点为第26周PANSS总分。
  • 纳入15-25岁首发精神病患者162名,在第4、8、12、26、52周评估。
  • 次要结局涵盖症状、功能、生活质量、神经认知及炎症、氧化应激、谷胱甘肽等机制指标。

核心结论

  • 该方案旨在确定辅助性NAC(2 g/天,26周)相比安慰剂能否改善首发精神病年轻患者的精神症状。
  • 研究同时探索NAC的神经生物学机制及其与26周和52周临床与功能结局的关系。

研究设计与样本

  • ENACT为26周随机安慰剂对照试验,另设26周非治疗随访期,比较辅助性NAC与安慰剂。
  • 计划招募162名15-25岁、近期就诊并正在澳大利亚墨尔本早期精神病预防与干预中心接受治疗的首发精神病年轻患者。

关键数值与推荐

  • 主要结局为阳性与阴性症状量表(PANSS)总分,在基线及第4、8、12、26周(主要终点)和第52周(研究结束)评估。
  • 次要结局包括症状学、功能、生活质量、神经认知,以及血液炎症、氧化和亚硝化应激指标和磁共振波谱测定的谷胱甘肽浓度。
  • 干预为辅助性NAC 2 g/天,持续26周。

临床怎么用

  • 若研究成功,可能为首发精神病提供一种针对神经生物学机制的新型辅助治疗选择。
  • 研究关注早期干预对首发精神病长期预后和功能结局的潜在改善。

局限性

  • 原文为试验方案,尚未报告疗效与安全性结果。
  • 招募对象限定为澳大利亚墨尔本单一早期干预中心就诊的15-25岁患者,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: First-episode psychosis (FEP) may lead to a progressive, potentially disabling and lifelong chronic illness; however, evidence suggests that the illness course can be improved if appropriate treatments are given at the early stages. Nonetheless, the efficacy of antipsychotic medications is suboptimal, particularly for negative and cognitive symptoms, and more efficacious and benign treatments are needed. Previous studies have shown that the antioxidant amino acid N-acetylcysteine (NAC) reduces negative symptoms and improves functioning in chronic schizophrenia and bipolar disorder. Research is scarce as to whether NAC is beneficial earlier in the course of illness. The primary aim of this study is to determine the efficacy of treatment with adjunctive NAC (2 g/day for 26 weeks) compared with placebo to improve psychiatric symptoms in young people experiencing FEP. Secondary aims are to explore the neurobiological mechanisms underpinning NAC and how they relate to various clinical and functional outcomes at 26- and 52-week follow-ups. METHODS/DESIGN: ENACT is a 26-week, randomised controlled trial of adjunctive NAC versus placebo, with a 26-week non-treatment follow-up period, for FEP. We will be recruiting 162 young people aged 15-25 years who have recently presented to, and are being treated at, the Early Psychosis Prevention and Intervention Centre, Melbourne, Australia. The primary outcome is the Total Score on the Positive and Negative Syndrome Scale which will be administered at baseline, and weeks 4, 8, 12, 26 (primary endpoint), and 52 (end of study). Secondary outcomes include: symptomatology, functioning, quality of life, neurocognition, blood-derived measures of: inflammation, oxidative and nitrosative stress, and magnetic resonance spectroscopy measures of glutathione concentration. DISCUSSION: Targeted drug development for FEP to date has generally not involved the exploration of neuroprotective agents. This study has the potential to offer a new, safe, and efficacious treatment for people with FEP, leading to better treatment outcomes. Additionally, the neuroprotective dimension of this study may lead to a better long-term prognosis for people with FEP. It has the potential to uncover a novel treatment that targets the neurobiological mechanisms of FEP and, if successful, will be a major advance for psychiatry. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, ID: ACTRN12618000413224. Registered on 21 March 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Cotton SM, Berk M, Watson A, et al. ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis. Trials. 2019. PMID: 31779696. doi:10.1186/s13063-019-3786-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。